We are already seeing the positive impact of these efforts, based on exceptional enrollment in the pivotal SOL-1 AXPAXLI study for wet AMD, coupled with plans for a new SOL-R repeat dosing study and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback